Dabigatran as alternative therapy in prothrombotic immune thrombocytopenia induced by the AstraZeneca SARS-Cov-2 vaccine

Abstract

Reviewing the treatment alternatives for thormbotic thrombocytopenia induced by vaccine (TTIV) after receiving a dose of ChAdOx1 nCov-19 vaccine (AstraZeneca) we observe that dabigatran should be an alternative to be considered since it has several strength points that may be useful in this pathology: Specific antidote, low level of interactions with others drugs and effectiveness in thrombotic events.